CL2017003295A1 - Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias - Google Patents

Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias

Info

Publication number
CL2017003295A1
CL2017003295A1 CL2017003295A CL2017003295A CL2017003295A1 CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1 CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1
Authority
CL
Chile
Prior art keywords
lymphocytosis
leukemias
lymphomas
induction
antibodies against
Prior art date
Application number
CL2017003295A
Other languages
English (en)
Inventor
Christian Klein
Carola Ries
Maria Teresa Sabrina Bertilaccio
Giovanni Galletti
CALIGARIS-CAPPIO Federico
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15173638.6A external-priority patent/EP3108897A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017003295A1 publication Critical patent/CL2017003295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A LA LINFOCITOSIS INDUCIDA POR ANTI-CSF-1R EN LINFOMAS Y LEUCEMIAS Y A UNA TERAPIA COMBINADA DE ANTICUERPOS QUE SE UNEN A CSF-1R HUMANO CON ANTICUERPOS QUE SE UNEN A CD20 HUMANO.</p>
CL2017003295A 2015-06-24 2017-12-21 Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias CL2017003295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15173638.6A EP3108897A1 (en) 2015-06-24 2015-06-24 Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP16151129 2016-01-13

Publications (1)

Publication Number Publication Date
CL2017003295A1 true CL2017003295A1 (es) 2018-06-01

Family

ID=56263686

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003295A CL2017003295A1 (es) 2015-06-24 2017-12-21 Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias

Country Status (16)

Country Link
US (1) US20180222985A1 (es)
EP (1) EP3313442B1 (es)
JP (1) JP6811733B2 (es)
KR (1) KR20180012873A (es)
CN (1) CN107847592B (es)
AU (1) AU2016282877A1 (es)
BR (1) BR112017027614A2 (es)
CA (1) CA2987716A1 (es)
CL (1) CL2017003295A1 (es)
CR (1) CR20170537A (es)
IL (1) IL256135A (es)
MX (1) MX2017016651A (es)
PE (1) PE20181050A1 (es)
RU (1) RU2018102575A (es)
WO (1) WO2016207312A1 (es)
ZA (1) ZA201708074B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
AU2018243104B2 (en) * 2017-04-01 2024-11-14 Beijing Hanmi Pharm. Co., Ltd. Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TWI772488B (zh) 2017-08-08 2022-08-01 瑞士商赫孚孟拉羅股份公司 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN109053888B (zh) * 2018-07-18 2020-06-19 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其用途
CN109053886B (zh) * 2018-07-18 2020-07-28 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及用途
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
TWI478940B (zh) * 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
AU2010329934B2 (en) * 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP2729498A1 (en) * 2011-07-06 2014-05-14 MorphoSys AG Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Also Published As

Publication number Publication date
IL256135A (en) 2018-02-28
JP6811733B2 (ja) 2021-01-13
ZA201708074B (en) 2018-11-28
CR20170537A (es) 2018-02-20
EP3313442B1 (en) 2019-10-16
CN107847592A (zh) 2018-03-27
PE20181050A1 (es) 2018-07-03
AU2016282877A8 (en) 2018-01-18
JP2018525339A (ja) 2018-09-06
HK1252860A1 (zh) 2019-06-06
CN107847592B (zh) 2022-01-21
BR112017027614A2 (pt) 2018-08-28
KR20180012873A (ko) 2018-02-06
MX2017016651A (es) 2018-05-14
US20180222985A1 (en) 2018-08-09
EP3313442A1 (en) 2018-05-02
RU2018102575A (ru) 2019-07-25
CA2987716A1 (en) 2016-12-29
WO2016207312A1 (en) 2016-12-29
AU2016282877A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CL2017003295A1 (es) Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2017002401A1 (es) Anticuerpos contra icos
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
AR101697A1 (es) Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2023005879A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX374290B (es) Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.
BR112015032224A2 (pt) anticorpos anti-fcrh5
MX370807B (es) Anticuerpos que se unen a axl.
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2